davidApril 15, 2021
MarketQuest.biz has published a new report titled
Global Novel Drug Delivery Systems Market 2020 by Company, Type and Application, Forecast to 2025 examines in-depth and accurate data regarding the market using diverse methodologies. The report highlights an in-depth analysis of the worldwide segments and sub-segments of the market that contributes to understanding the present status of the global Novel Drug Delivery Systems market. The report presents business outlooks like global market shares, drivers, restraints, recent innovative trends, and challenges before the market. The study provides the overall scenario and dynamics of the global market with its definition and other details. Further, the key player and competitive landscape segment of the report enlist the various players actively participating and competing in the global market.
Bicycle Therapeutics Announces Presentations at the AACR Annual Meeting 2021
- BT7480 to be presented in a “New Drugs on the Horizon” session; on-track to enter the clinic in 2H’21
CAMBRIDGE, England & BOSTON (BUSINESS WIRE) Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (
Bicycle®) technology, today announced that for the first time, preclinical work describing the discovery of BT7480, a novel Nectin-4/CD137 tumor-targeted immune cell agonist (TICA
TM), will be presented virtually in a “New Drugs on the Horizon” session at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 10-15, 2021. Additional work covering TICAs and
Bicycle Therapeutics plc: Bicycle Therapeutics Announces Presentations at the AACR Annual Meeting 2021
- BT7480 to be presented in a New Drugs on the Horizon session; on-track to enter the clinic in 2H 21
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (
Bicycle) technology, today announced that for the first time, preclinical work describing the discovery of BT7480, a novel Nectin-4/CD137 tumor-targeted immune cell agonist (TICA
TM), will be presented virtually in a New Drugs on the Horizon session at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 10-15, 2021. Additional work covering TICAs and
Global Novel Drug Delivery Systems (NDDS) Market to Reach $27. 2 Billion by 2027. Amid the COVID-19 crisis, the global market for Novel Drug Delivery Systems (NDDS) estimated at US$7. 7 Billion in the year 2020, is projected to reach a revised size of US$27.New York, Jan. 19, 2021 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report "Global Novel Drug Delivery Systems (NDDS) Industry" - https://www.reportlinker.com/p05957531/?utm source=GNW 2 Billion by 2027, growing at aCAGR of 19.7% over the period 2020-2027. Nanoparticles, one of the segments analyzed in the report, is projected to record 19% CAGR and reach US$23.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Embolization Particles segment is readjusted to a revised 24.7% CAGR for the next 7-year period. The U.S. Market is Estimated at $2.3 Billion, While China is Forecast to Grow at 19.3% CA